Compare CBU & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | NAMS |
|---|---|---|
| Founded | 1866 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 1994 | N/A |
| Metric | CBU | NAMS |
|---|---|---|
| Price | $66.82 | $35.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $66.67 | $46.75 |
| AVG Volume (30 Days) | 394.6K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $818,007,000.00 | N/A |
| Revenue This Year | $13.46 | $17.96 |
| Revenue Next Year | $7.75 | $540.65 |
| P/E Ratio | $61.38 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $51.12 | $20.53 |
| 52 Week High | $69.23 | $42.21 |
| Indicator | CBU | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 57.67 |
| Support Level | $60.90 | $33.83 |
| Resistance Level | $66.99 | $37.27 |
| Average True Range (ATR) | 1.45 | 1.74 |
| MACD | -0.07 | 0.42 |
| Stochastic Oscillator | 67.75 | 71.06 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional, and governmental customers. The Company also offers comprehensive financial planning, trust administration, and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services, and Wealth Management Services. The group generates the majority of its revenue from the Banking and Corporate segment.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.